Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2024-01-11 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
2024年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled "2024年第一次临时 股东大会 会议资料" which translates to "2024 First Extraordinary General Meeting (EGM) Meeting Materials." It contains detailed agenda items, including proposals for acquisition of 55% equity in Wuhan Mingshi Pharmaceutical Co., Ltd., amendments to shareholder meeting rules, voting procedures, and legal opinions. The document includes extensive information about the acquisition transaction, financial audit reports, asset valuation, and voting instructions. This is clearly a set of materials prepared for a shareholders' meeting, specifically an extraordinary general meeting, and not a full annual report, earnings release, or other financial report. It is not merely an announcement or a brief notice but detailed meeting materials. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings).
2024-01-11 Chinese
2024-002 关于收购武汉名实药业股份有限公司55%股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 55% equity in Wuhan Mingshi Pharmaceutical Co., Ltd. by Qidi Pharmaceutical Group Co., Ltd. It includes transaction overview, parties involved, financial data, asset evaluation reports, board meeting resolutions, and risk analysis. The content focuses on a capital transaction involving share acquisition, payment terms, and related approvals. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a regulatory filing or announcement of a report publication but a substantive update on a financing/capital transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-01-11 Chinese
关于召开2024年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东大会) of shareholders for a company, including meeting date, voting procedures, agenda items, and proxy forms. It does not contain financial statements or results but rather the announcement and procedural information for the shareholder meeting. The document length is 3808 characters, which is relatively short and consistent with a meeting notice rather than a full report. It includes agenda proposals for shareholder voting, meeting logistics, and proxy instructions. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a voting results announcement or management change notice. Therefore, the best classification is PSI with high confidence.
2024-01-11 Chinese
第十届董事会临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a temporary board meeting of the company. It details decisions on acquisitions, investments, guarantees, committee member adjustments, governance rule revisions, and scheduling of a shareholders meeting. The text includes voting results and references to further announcements published elsewhere. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (2249 characters), and it is not merely announcing a report publication but providing substantive board decisions. Therefore, the classification is MANG with high confidence.
2024-01-11 Chinese
关于全资子公司取得药品经营许可证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the acquisition of a pharmaceutical business license by a wholly-owned subsidiary of the company. It details the license information, the impact on the company, and related approvals. There is no financial data, no report attached or referenced as being published, and no mention of regulatory certifications or filings. The document is a regulatory announcement about a business license acquisition, which does not fit into financial reports or management reports categories. It is best classified as a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-12-29 Chinese
关于控股股东部分股份被司法拍卖的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the progress of a judicial auction of shares held by the company's controlling shareholder. It details the number of shares auctioned, the buyers, and the impact on shareholding percentages. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management commentary. The document is an update on a shareholder-related event, specifically a judicial auction of shares, which fits best under a regulatory announcement category. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a voting result or a capital change announcement but a regulatory disclosure about shareholding changes due to judicial auction. Therefore, the best classification is Regulatory Filings (RNS). The document length is short (1613 characters), and it is a standalone announcement, not a report or presentation.
2023-12-22 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.